CRISPR dispute raises bigger patent issues that we're not talking about

Opinion

 Consider a similar situation, the now-famous case of biotechnology company Myriad Genetics’ patents on the BRCA genes, which confer increased susceptibility for breast and ovarian cancer.

 And in the future, we should seriously consider the importance of the patent system – almost by default – in shaping the moral dimensions of science and technology.